Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus

Journal of Rheumatology

Volumn 29, Issue 9, 2002, Pages 1858-1866

  Kobayashi, Hiroshi ^a   Hosono, Osamu ^a   Mimori, Tsuneyo ^a   Kawasaki, Hiroshi ^a   Dang, Nam Hoang ^a   Tanaka, Hirotoshi ^a   Morimoto, Chikao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Dipeptidyl peptidase IV; Disease activity; Soluble CD26; Systemic lupus erythematosus

Indexed keywords

DIPEPTIDYL PEPTIDASE IV;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CELL SURFACE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DOMAIN; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD26; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; DIPEPTIDYL PEPTIDASES; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROBABILITY; PROGNOSIS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SOLUBILITY;

EID: 0036735330     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody
2. 1F7, a novel cell surface molecule, involved in helper function of CD4 cells
3. The structure and function of CD26 in the T-cell immune response
4. CD26, let it cut or cut it down
5. The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity
6. Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation
7. Evidence for recent as well as long term activation of T cells migrating through endothelial cell monolayers in vitro
8. Phenotypic characterization of CD4+ T cells that exhibit a transendothelial migratory capacity
9. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage
10. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection
11. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: Possible mechanism for the switch from innate to acquired immune response
12. Negative regulation of the anti-human immunodeficiency virus and chemotactic activity of human stromal cell-derived factor 1 alpha by CD26/dipeptidyl peptidase IV
13. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1 alpha
14. Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways
15. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity
16. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes
17. Direct association of adenosine deaminase with a T cell activation antigen, CD26
18. Ecto-ADA in the development of the immune system
19. Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor II receptor contributes to T cell activation
20. Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV
21. Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs
22. Elevated in vivo expression of the costimulatory molecule B7-BB1 (CD80) on antigen presenting cells from a patient with SLE
23. Expression of costimulatory molecule CD80 on peripheral blood T cells in patients with systemic lupus erythematosus
24. Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients
25. Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus: A possible mechanism for lymphopenia
26. Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus
27. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes
28. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production
29. Soluble interleukin-2 receptor levels in lupus nephritis
30. Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocyte count and disease course
31. Soluble CD23 levels are elevated in the serum of patients with primary Sjogren's syndrome and systemic lupus erythematosus
32. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases
33. Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis
34. Relationship between lupus nephritis activity and the serum level of soluble VCAM-1
35. A study of increased levels of soluble vascular cell adhesion molecule-1 in the cerebrospinal fluid of patients with multiple sclerosis and systemic lupus erythematosus
36. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: Correlations with the severity of thrombosis
37. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus; a longterm prospective study
38. Elevated soluble E-selectin in cutaneous lupus erythematosus
39. The soluble CD40 ligand sCD154 in systemic lupus erythematosus
40. Serum glycylproline p-nitroanilidase activity in rheumatoid arthritis and systemic lupus erythematosus
41. Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in mice with lupus erythematosus-like syndrome and in patients with lupus erythematosus and rheumatoid arthritis
42. Dipeptidyl peptidase IV in patients with systemic lupus erythematosus
43. Fluorogenic substrates for bacterial aminopeptidase P and its analogs detected in human serum and calf lung
44. A novel form of dipeptidylpeptidase IV found in human serum. Isolation, characterization, and comparison with T lymphocyte membrane dipeptidylpeptidase IV (CD26)
45. Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells
46. Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis
47. Dipeptidyl-peptidase IV-beta, a novel form of cell-surface-expressed protein with dipeptidyl-peptidase IV activity
48. Dipeptidyl-peptidase IV-beta - Further characterization and comparison to dipeptidyl-peptidase IV activity of CD26
49. The 1982 revised criteria for the classification of systemic lupus erythematosus
50. Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals
51. Dipeptidyl peptidase IV from human serum: Purification, characterization, and N-terminal amino acid sequence
52. Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis
53. Decreased expression and release of dipeptidyl peptidase IV (CD26) in cultured peripheral blood T lymphocytes of oral cancer patients
54. Reduced expression of dipeptidyl peptidase (DPP) IV in peripheral blood T lymphocytes of oral cancer patients
55. Preoperative serum CD26 levels: Diagnostic efficiency and predictive value for colorectal cancer
56. Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy
57. Dipeptidyl peptidase IV and adenosine deaminase activity. Decrease in depression
58. Activities of dipeptidyl peptidases in BXSB mice and MRL/lpr mice with lupus erythematosus-like syndrome
59. Dipeptidyl peptidase IV (DP IV) activity in serum and on lymphocytes of MRL/Mp-lpr/lpr mice correlates with disease onset
60. Increased population of high fluorescence 1F7 (CD26) antigen on T cells in synovial fluid of patients with rheumatoid arthritis